维普期刊资源整合服务平台（V6.5）

299篇 您的检索式：作者名="Haffner M"

选中清除导出查看参考文献查看引证文献引用追踪共15页首页上一页第1页下一页末页 /15 跳转

	题名	作者	年代	出处	被引量
1	Cardiovascular risk factors and the prediabetic syndrome显示文摘	Haffner S M	1996	Ann Med1996，28，：	1
2	A prospective analysis of the HOMA model显示文摘	Haffner S M Gonzalez C Miettinen H	1996	The Mexic City Diabetes Staty Diabetes Care1996，19，10：	1
3	Sex hormone-binding protein,hyperinsulinemia,insulin resistance and noninsulin-dependent diabetes显示文摘	Haffner S M	1996	Horm Res1996，45，23：	1
4	Accuracy of electronic apex locators in comparison to actual length--an in vivo study显示文摘	Haffner C Folwaczny M Galler K		0，，08：	1
5	Regulation of arginase-1 expression in macrophages by a protein kinase A type I and histone deacetylase dependent pathway显示文摘	Haffner I Teupser D Holdt L M	2008	J Cell Biochem2008，103，：	1
6	Orphan drug product regulation--United States显示文摘	Haffner M	2002	Int J Clin Pharmacol Ther2002，40，2：	1
7	Nicalin and its bindingpartner Nomo are novel Nodal signaling antagonists 显示文摘	Haffner C Frauli M Topp S	2004	EMBO Journal2004，23，15：	1
8	Mortality from coronary heart diasease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior mycardial infarction 显示文摘	Haffner SM Lehto S Ronnemaa T Pyorala K Laakso M	1998	N Engl J Med1998，339，4：	1
9	Combination of methylated-DNA precipitation and methylationsensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation显示文摘	Yegnasubramanian S Lin X Haffner M C	2006	Nucleic Acids Res2006，34，3：	1
10	Sleep durationas a risk factor for inlident type 2 diabetes in aMultietlmic显示文摘	Beihl D A Liese A D Haffner S M	2009	Ann Epidemiol2009，19，5：	1
11	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial 显示文摘	Califf R M Boolell M Haffner S M	2008	Am Heart J2008，156，4：	1
12	Proinsulin and insulin concentrations in relation to carotid wall thickness显示文摘	Haffner S M D'Agostino R Mykkanen L	1998	Stroke1998，29，：	1
13	Accuracy of electronic apex lacators in comparison to actual length - an in vivo study 显示文摘	Haffner C Fotwaczny M Galler K	2005	Journal of Dentistry2005，33，8：	1
14	Two decades of orphan product development显示文摘	Haffner M E Whitley J and Moses M	2002	Nat Rev Drug Diseov2002，1，10：	1
15	Molecular cloning, structural analysis and functional expression of the proline-rich focal adhesion and microfilament-associated protein VASP显示文摘	Haffner C Jarchau T Reinhard M	1995	EMBO J1995，14，：	1
16	Does orphan drug legislation really answer the need of patients显示文摘	HAFFNER M E TORRENT-FARNELL J MAHER P D	2008	Lancet2008，371，9629：	1
17	Loss of P53 function through PAX-mediated transcriptional repression显示文摘	Haffner R Oren M	1995	EMBOJ1995，14，22：	1
18	Insulin-resistant patients with type2 diabetes mellitus have higher serum leptin levels independently of body fat mass显示文摘	Fischer S Hanefeld M Haffner S M	2002	Acta Diabetol2002，39，3：	1
19	Reduced coronary events in simvastatintreated payients with coronary heart disease and diabetes or impaired fasting glucose levels:subgroup analyses in the Scandinavian Simvastatin Survival Study显示文摘	Haffner S M Alexander C M Cook T J	1999	Arch Intern Med1999，159，22：	1
20	The Food and Drug Administration's Office of Orphan Products Development:incentives,grants,and special designations speed therapies for orphan diseases显示文摘	Haffner M E	2005	Retina2005，25，8：	1

返回顶部每页显示：

共15页首页上一页第1页下一页末页 /15 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示